Prana Biotechnology Limited (NASDAQ:PRAN) and Medbox Inc. (NASDAQOTH:MDBX) were the big losers in the health-care space today, and in this segment from Wednesday's Market Checkup, Motley Fool health-care analyst David Williamson looks at what caused these two market nosedives.
Prana released phase 2 trial results for its leading drug candidate PBT2 in its Huntington's disease indication. While the drug hit its safety endpoint, there is still considerable debate over the drug's efficacy, with the company calling the trial a success, while critics looking at the overall data have called it a failure. Shares are down 10% on the news. David discusses the future of Prana and PBT2 in both its Huntington's and Alzheimer's disease indications, and advises investors to be sure they know the risks involved here.
Also, Medbox Inc. took a verbal lashing from the famed bearish blog Citron Research today, driving shares down by 7%. The company offers marijuana dispensing machines and consulting services for distributors, and in the video, David notes that he's surprised the stock isn't down further after Citron called it "worthless," and attacked both the validity of the company's financials and the history of its CEO. David advises that while many investors are very eager today to get in on the ground floor of the potential future marijuana sales boom, that the risks involved in this yet uncertain industry are still extremely high, and that waiting until the dust settles further could be a very wise move.
How savvy investors play the biotech sector
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.